青光安Ⅱ号方治疗青光眼的分子机制研究  

Study on the molecular mechanism of Qingguangan Ⅱ Formula for glaucoma

作　　者：蒋鹏飞[1,2] 彭俊 曾志成[1] 刘培[1] 彭清华 JIANG Peng-fei;PENG Jun;ZENG Zhi-cheng;LIU Pei;PENG Qing-hua(Hunan University of Chinese Medicine,Changsha 410208,China;Hunan Provincial Key Laboratory for the Prevention and Treatment of Ophthalmology and Otolaryngology Diseases with Traditional Chinese Medicine,Changsha 410208,China;First Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)

机构地区：[1]湖南中医药大学,长沙410208 [2]中医药防治眼耳鼻咽喉疾病湖南省重点实验室,长沙410208 [3]湖南中医药大学第一附属医院,长沙410007

出　　处：《中华中医药杂志》2021年第7期4219-4222,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金面上项目(No.81874492);中医药防治五官科疾病湖南省重点实验室开放基金项目(NO.2018YZD02);国家中医药管理局中医眼科学重点学科建设项目(NO.ZK1801YK015);湖南中医药大学中医学国内一流建设学科开放基金重点项目(No.2021ZYX13);湖南省自然科学基金青年基金项目(No.2020JJ5436);湖南中医药大学“一方”研究生创新项目(No.2021YF03)。

摘　　要：目的:基于网络药理学探讨青光安Ⅱ号方治疗青光眼的分子机制。方法:通过TCMSP筛选和预测青光安Ⅱ号方潜在的入血活性成分和作用靶点;通过疾病基因数据库挖掘青光眼相关的靶点;采用STRING数据库绘制成分-靶点和疾病-靶点的PPI网络,并提取这两个网络的交集;采用DAVID 6.8数据库分析筛选关键靶点与作用机制。结果:在TCMSP数据库共检索出与青光安Ⅱ号方相关的潜在活性成分808个,根据药代动力学参数筛选获得102个潜在入血活性成分,并检索出与这些成分相关的靶点1 018个;从疾病基因数据库检索并筛选得到与青光眼直接相关的靶点82个;成分靶点和疾病靶点PPI网络取交集后得到以乙酰胆碱受体、肾上腺素受体为主的14个关键蛋白;这些蛋白主要涉及到神经活性配体-受体相互作用、钙信号通路等。结论:青光安Ⅱ号方能通过乙酰胆碱受体、肾上腺素受体等14个关键蛋白治疗青光眼,其机制可能与降低眼压相关。Objective: To explore the molecular mechanism of Qingguangan Ⅱ Formula for glaucoma based on network pharmacology. Methods: Screening and prediction of possible blood-supplying active ingredients and gene targets of Qingguangan Ⅱ Formula through TCMSP;mining gene targets related to glaucoma through the disease gene database;using STRING database to draw component-target and disease-target PPI Network, and extract the intersection of these two networks;use DAVID database analysis to screen key targets and action mechanism. Results: A total of 808 active ingredients related to Qingguangan Ⅱ Formula were retrieved from the TCMSP database. A total of 102 blood-supplying active ingredients were obtained by screening based on pharmacokinetic parameters, and 1018 targets related to these ingredients were retrieved. From the disease Gene database search for disease screening revealed 82 genes directly related to glaucoma;14 key proteins were obtained after the intersection of the component target and disease target PPI network;These proteins are mainly involved in neuroactive ligand-receptor interaction, calcium signaling pathway, etc. Conclusion: Qingguangan Ⅱ Formula can treat glaucoma through 14 key proteins, such as acetylcholine receptor and adrenergic receptor, and its mechanism may be related to lowering intraocular pressure.

关 键 词：青光安Ⅱ号方 青光眼 网络药理学 生物信息学 

分 类 号：R285[医药卫生—中药学]